Strides Shasun has received an Establishment Inspection Report (EIR) from the US health regulator for its formulations facility at Bengaluru.
“The company’s formulations facility (KRSG Gardens) in Bengaluru, which was inspected by the USFDA in May 2017, has received the EIR, thereby confirming the closure of the inspection,” Strides said in a BSE filing today.
The KRSG Gardens facility manufactures tablets, capsules, liquids, sachets, creams and ointments. The facility supports important current and future products for the US market.
Shares of Strides Shasun were trading at Rs 927.50 apiece, up 2.10 per cent from the previous close on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.